UK markets close in 5 hours 11 minutes

  • FTSE 100

    6,881.68
    -7.44 (-0.11%)
     

  • FTSE 250

    22,195.56
    +42.01 (+0.19%)
     

  • AIM

    1,238.85
    +4.16 (+0.34%)
     

  • GBP/EUR

    1.1555
    +0.0024 (+0.21%)
     

  • GBP/USD

    1.3744
    +0.0002 (+0.01%)
     

  • BTC-GBP

    45,710.54
    +1,250.47 (+2.81%)
     

  • CMC Crypto 200

    1,334.15
    +39.56 (+3.06%)
     

  • S&P 500

    4,127.99
    -0.81 (-0.02%)
     

  • DOW

    33,745.40
    -55.20 (-0.16%)
     

  • CRUDE OIL

    60.22
    +0.52 (+0.87%)
     

  • GOLD FUTURES

    1,725.70
    -7.00 (-0.40%)
     

  • NIKKEI 225

    29,751.61
    +212.88 (+0.72%)
     

  • HANG SENG

    28,497.25
    +43.97 (+0.15%)
     

  • DAX

    15,273.45
    +58.45 (+0.38%)
     

  • CAC 40

    6,191.02
    +29.34 (+0.48%)
     
COVID impact:

Furniture and men's clothing spur UK retail recovery as Britain's shops reopen

2020 was a turbulent year in which much of retail bounced between being open and closed

Assistant and friend to deceased Zappos CEO files $90M lawsuit against estate

Josh Marcus
·2-min read
<p>Tony Hsieh, CEO of Zappos, responds to questions from interviewer Dennis Berman at 2015 WSJD Live on October 20, 2015 in Laguna Beach, California. </p> (AFP via Getty Images)

Tony Hsieh, CEO of Zappos, responds to questions from interviewer Dennis Berman at 2015 WSJD Live on October 20, 2015 in Laguna Beach, California.

(AFP via Getty Images)

A longtime friend, assistant, and business associate of recently deceased Zappos founder Tony Hsieh took his family to court this week, filing more than $90 million worth of creditor’s claims she argues she is owed under contracts with the mogul, the LasVegas Review-Journal reports.

Jennifer “Mimi” Pham was a close friend and long-time assistant to Mr Hsieh, 46, who became a millionaire after selling the online shoe retailer Zappos to Amazon. He died in November in a house fire in Connecticut, leaving no will, and inspiring lawsuits over what to do with his vast estate

One claim from Ms Pham, a friend so close she and Mr Hsieh reportedly shared a cell phone number and address, is for $75 million, representing the “anticipated profit” for a deal with Documentary+, a documentary streaming service she helped Mr Hsieh invest in. Another, worth $7.5 million, relates to her management of another Hsieh venture, the Big Moose Yacht Club in Park City, Utah, which she helped manage.

Attorneys for both parties did not respond to a request for comment.

Ms Pham alleges that Mr Hsieh’s family took over his business affairs after his death and isn’t honouring agreements she made with the prominent investor.

The former Zappos boss died in November from complications from smoke inhalation, after an accidental house fire broke out at a $1.3 million waterfront property in New London, Connecticut, and he was trapped in a storage area and unable to escape.

Close friends told the Wall Street Journal that the lauded executive had been on a downward spiral after retiring from Zappos, and struggled with substances and isolation during the pandemic, as well as a fixation with fire and extreme starvation diets that worried those close to him. He reportedly made plans to check into a rehab clinic a day before the fire.

Mr Hsieh was beloved in Las Vegas, and was a major force behind revitalizing its downtown, investing hundreds of millions of dollars into startups, property, restaurants, and other ventures in the area, some of which his family has moved to sell after his death.

Read More

Tony Hsieh: Zappos boss dies after accidental house fire

Tony Hsieh, retired Zappos CEO, dies at 46

Zappos' new 'Holacracy' management system: No managers, no hierarchy - or you can leave

Latest stories

  • Pub-goers should still remain cautious despite lockdown easing, expert warns

    Drinkers should still follow government guidelines and take precautions against Covid-19 even when outside enjoying beer gardens, an expert has said. Professor Adam Finn, a member of the Joint Committee on Vaccination and Immunisation , said Britons should still continue to socially distance in the “coming weeks and months” despite the success of the UK vaccine programme. Prof Finn’s comments came as the country entered phase two of the Government’s roadmap out of lockdown, with pub beer gardens and restaurants are now able to serve customers outdoors, and non-essential retailers and hairdressers also allowed to reopen.

  • True Mothers review – Naomi Kawase's heartfelt yet frustrating drama

    True Mothers review – Naomi Kawase's heartfelt yet frustrating drama. The director of The Mourning Forest returns with another sensitive film, this time about a difficult adoption, yet plot holes prove distracting

  • Kurds impose 10-day curfew in NE Syria amid coronavirus wave

    A 10-day curfew in areas controlled by U.S.-backed fighters in northeast Syria went into effect Tuesday in an attempt to try limit the spread of coronavirus in the region that borders Turkey and Iraq. Residents in northeast Syria contacted by telephone said most people were abiding by the lockdown with few people on the streets amid patrols and checkpoints enforcing the curfew. In addition to the curfew, all crossing points between areas held by the Kurdish-led Syrian Democratic Forces with areas held by government forces and those with insurgent groups in northwest Syria will be closed as well.

  • Global Tents (Including Caravan Awnings) Market to 2025 - Analysis, Forecast, Size, Trends and Insights - ResearchAndMarkets.com

    The "World - Tents (Including Caravan Awnings) - Market Analysis, Forecast, Size, Trends and Insights" report has been added to ResearchAndMarkets.com's offering.

  • Richard Rush, Oscar-nominated director of The Stunt Man, dies aged 91

    Richard Rush, Oscar-nominated director of The Stunt Man, dies aged 91. The film-maker’s early underground work included Hells Angels on Wheels before he entered the mainstream with hits such as Freebie and the Bean

  • Ingevity announces details for upcoming webinar on activated carbon’s runway with the internal combustion engine

    Ingevity will hold a live webinar to discuss activated carbon’s runway with the internal combustion engine on April 14, 2021, at 10 a.m. (EST).

  • These fun Russian twist variations will fire up your obliques

    Build the strength and power necessary to improve running speed and efficiency on flat ground and hills alike.

  • Nornickel to boost output of nickel products in Finland for EV battery market

    Russian metals producer Nornickel said on Tuesday it will boost output of nickel products at its Harjavalta plant in Finland as it bets on the expanding market for battery materials needed for electric vehicles (EV). Finland's state mining investment firm Finnish Minerals Group, German chemicals giant BASF and Finnish utility Fortum are among companies currently forming an EV battery cluster in Finland.

  • Home Office faces inquiry into use of barracks to house asylum seekers

    Home Office faces inquiry into use of barracks to house asylum seekers. Cross-party MPs and peers concerned about ‘quasi-detention’ of vulnerable people

  • Worldwide Infant Formula Industry to 2025 - Players Include Nestle, Danone and Mead Johnson Among Others - ResearchAndMarkets.com

    The "Infant Formula Global Market Insights 2020, Analysis and Forecast to 2025, by Manufacturers, Regions, Technology, Application, Product Type" report has been added to ResearchAndMarkets.com's offering.

  • Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report 2021: Methods of Commercializing iPSCs are Diverse and Continue to Expand

    Dublin, April 13, 2021 (GLOBE NEWSWIRE) -- The "Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report 2021" report has been added to ResearchAndMarkets.com's offering. The main objectives of this report are to describe the current status of iPSC research, patents, funding events, industry partnerships, biomedical applications, technologies, and clinical trials for the development of iPSC-based therapeutics. Since the discovery of induced pluripotent stem cells (iPSCs) a large and thriving research product market has grown into existence, largely because the cells are non-controversial and can be generated directly from adult cells. It is clear that iPSCs represent a lucrative market segment because methods for commercializing this cell type are expanding every year and clinical studies investigating iPSCs are swelling in number.Therapeutic applications of iPSCs have surged in recent years. 2013 was a landmark year in Japan because it saw the first cellular therapy involving the transplant of iPSCs into humans initiated at the RIKEN Center in Kobe, Japan. Led by Masayo Takahashi of the RIKEN Center for Developmental Biology (CDB), it investigated the safety of iPSC-derived cell sheets in patients with macular degeneration. In another world-first, Cynata Therapeutics received approval in 2016 to launch the world's first formal clinical trial of an allogeneic iPSC-derived cell product (CYP-001) for the treatment of GvHD. Riding the momentum within the CAR-T field, Fate Therapeutics is developing FT819, its "off-the-shelf" iPSC-derived CAR-T cell product candidate. Numerous physician-led studies using iPSCs are also underway in Japan, a leading country for basic and applied iPSC applications.iPS Cell Market CompetitorsToday, FUJIFILM CDI has emerged as one of the largest commercial players within the iPSC sector. FUJIFILM CDI was founded in 2004 by Dr. James Thomson at the University of Wisconsin-Madison, who in 2007 derived iPSC lines from human somatic cells for the first time ever. The feat was accomplished simultaneously by Dr. Shinya Yamanaka's lab in Japan.In 2009, ReproCELL, a company established as a venture company originating from the University of Tokyo and Kyoto University, made iPSC products commercially available for the first time with the launch of its human iPSC-derived cardiomyocytes, which it called ReproCario.A European leader within the iPSC market is Ncardia, formed through the merger of Axiogenesis and Pluriomics. Founded in 2001, Axiogenesis initially focused on generating mouse embryonic stem cell-derived cells and assays, but after Yamanaka's iPSC technology became available, it became the first European company to license it in 2010. Ncardia's focus is on preclinical drug discovery and drug safety through the development of functional assays using human neuronal and cardiac cells. In total, at least 68 distinct market competitors now offer various types of iPSC products, services, technologies and therapies. iPS Cell CommercializationMethods of commercializing induced pluripotent stem cells (iPSCs) are diverse and continue to expand. iPSC cell applications include, but are not limited to: Research Products: Market competitors provide iPSC specific tools to scientists worldwide, including human iPSC lines and differentiated cell types, as well as optimized reagents, protocols, differentiation kits, and more.Drug Development & Discovery: iPSCs have the potential to transform drug discovery by providing physiologically relevant cells for compound identification, target validation, compound screening, and tool discovery.Cellular Therapy: iPSCs are being explored in a diverse range of cell therapy applications for the purpose of reversing injury or disease.Toxicology Screening: iPSCs can be used for toxicology screening, which is the use of stem cells or their derivatives (tissue-specific cells) to assess the safety of compounds or drugs within living cells.Personalized Medicine: The use of techniques such as CRISPR enables precise, directed the creation of knock-outs and knock-ins (including single-base changes) in many cell types. Pairing iPSCs with genome editing technologies has added a new dimension to personalized medicine.Disease Modelling: By generating iPSCs from patients with disorders of interest and differentiating them into disease-specific cells, iPSCs can effectively create disease models "in a dish."Stem Cell Banking: iPSC repositories provide researchers with the opportunity to investigate a diverse range of conditions using iPSC-derived cell types produced from both healthy and diseased donors.Other Applications: Other applications for iPSCs include areas like tissue engineering, 3D bioprinting, clean meat production, wildlife conservation, and more. Since the discovery of iPSC technology in 2006, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified and explained, new drugs identified by iPSC screens are in the pipeline, and the first clinical trials employing human iPSC-derived cell types have been initiated. Key Topics Covered: 1. REPORT OVERVIEW1.1 Statement of the Report1.2 Executive Summary 2. INTRODUCTION2.1 Discovery of iPSCs2.2 Barriers in iPSC Application2.3 Timeline and Cost of iPSC Development2.4 Current Status of iPSCs Industry2.4.1 Share of iPSC-based Research within the Overall Stem Cell Industry2.4.2 Major Focuses of iPSC Companies2.4.3 Commercially Available iPSC-Derived Cell Types2.4.4 Relative Use of iPSC-Derived Cell Types in Toxicology Testing Assays2.4.5 Toxicology/Safety Testing Assays using iPSC-Derived Cell Types2.5 Currently Available iPSC Technologies2.6 Advantages and Limitations of iPSCs Technology 3. HISTORY OF INDUCED PLURIPOTENT STEM CELLS (IPSCS)3.1 First iPSC generation from Mouse Fibroblasts, 20063.2 First Human iPSC Generation, 20073.3 Creation of CiRA, 20103.4 First High-Throughput screening using iPSCs, 20123.5 First iPSCs Clinical Trial Approved in Japan, 20133.6 The First iPSC-RPE Cell Sheet Transplantation for AMD, 20143.7 EBiSC Founded, 20143.8 First Clinical Trial using Allogeneic iPSCs for AMD, 20173.9 Clinical Trials for Parkinson's disease using Allogeneic iPSCs, 20183.10 Commercial iPSC Plant SMaRT Established, 20183.11 First iPSC Therapy Center in Japan, 2019 4. RESEARCH PUBLICATIONS ON iPSCS4.1 Categories of Research Publications4.2 Percent Share of Published Articles by Disease Type4.3 Number of Articles by Country 5. IPSCS: PATENT LANDSCAPE5.1 Timeline and Status of Patents5.2 Patent Filing Destinations5.2.1 Patent Applicant's Origin5.2.2 Top Ten Global Patent Applicants5.2.3 Collaborating Applicants of Patents5.3 Patent Application Trends iPSC Preparation Technologies5.4 Patent Application Trends in iPSC Differentiation Technologies5.5 Patent Application Trends in Disease-Specific Cell Technologies 6. CLINICAL TRIALS INVOLVING iPSCS6.1 Current Clinical Trials Landscape6.1.1 Clinical Trials Involving iPSCs by Major Diseases6.1.2 Clinical Trials Involving iPSCs by Country 7. FUNDING FOR iPSCs7.1 Value of NIH Funding for iPSCs7.1.1 NHI's Intended Funding Through its Component Organizations in 20207.1.2 NIH Funding for Select Universities for iPSC Studies7.2 CIRM Funding for iPSCs 8. GENERATION OF INDUCED PLURIPOTENT STEM CELLS: AN OVERVIEW8.1 Reprogramming Factors8.2 Overview of Four Key Methods of Gene Delivery8.3 Comparative Effectiveness of Different Vector Types8.4 Genome Editing Technologies in iPSCs Generation 9. HUMAN iPSC BANKING9.1 Cell Sources for iPSCs Banking9.2 Reprogramming methods used in iPSC Banking9.3 Workflow in iPSC Banks9.4 Existing iPSC Banks 10. BIOMEDICAL APPLICATIONS OF iPSCS10.1 iPSCs in Basic Research10.2 iPSCs in Drug Discovery10.3 iPSCs in Toxicology Studies10.4 iPSCs in Disease Modeling10.5 iPSCs within Cell-Based Therapies 11. OTHER NOVEL APPLICATIONS OF iPSCS11.1 iPSCs in Tissue Engineering11.2 iPSCs in Animal Conservation11.3 iPSCs and Cultured Meat 12. DEAL-MAKING WITHIN THE iPSC SECTOR12.1 License Agreement between FUJIFILM Cellular Dynamics and Sana12.2 Century Therapeutics Closes $160 Million Series C Financing12.3 Bluerock Gains Access to Ncardia's iPSCs-derived Cardiomyocytes12.4 Fate Therapeutics' Deal with Janssen Biotech12.5 Century Therapeutics Acquires Empirica Therapeutics12.6 $250 Million Raised by Century Theraputics12.7 BlueRock Therapeutics Launched with $225 Million12.8 Collaboration between Allogene Therapeutics and Notch Therapeutics12.9 Acquisition of Semma Therapeutics by Vertex Therapeutics12.10 Evotec's Extended Collaboration with BMS12.11 Licensing Agreement between Allele Biotechnology and Astellas12.12 Codevelopment Agreement between Allele & SCM Lifesciences12.13 Fate Therapeutics Signs $100 Million Deal with Janssen12.14 Allele's Deal with Alpine Biotherapeutics12.15 Editas and BlueRock's Development Agreement 13. MARKET OVERVIEW13.1 Global Market for iPSCs by Geography13.2 Global Market for iPSCs by Technology13.3 Global Market for iPSCs by Biomedical Application13.4 Global Market for iPSCs by Cell Types3.5 Market Drivers13.6 Market Restraints 14. COMPANY PROFILES Addgene, Inc.Aleph FarmsAllele Biotechnology and Pharmaceuticals, Inc.ALSTEM, INC.American Type Culture Collection (ATCC)AMS Biotechnology Europe, Ltd. (AMSBIO)Applied Biological Materials, Inc. (ABM)Applied StemCell (ASC), Inc.Aruna Bio, Inc.Aspen Neuroscience, Inc.Axol Bioscience, Ltd.BD BiosciencesBeckman Coulter Life SciencesBioCat GmbHBlueRock TherapeuticsBrainXellCell Biolabs, Inc.Cell Signaling TechnologyCellariaCellGenix GmbHCellular Dynamics International, Inc.Cellular Engineering Technologies (CET)Censo Biotechnologies, Ltd.Century Therapeutics, LLCCiRACorning, Inc.Creative BioarrayCynata Therapeutics Ltd.Cytovia TherapeuticsDefiniGENEvotec SEFate Therapeutics, Inc.FUJIFILM Cellular Dynamics, Inc.GeneCopoeia, Inc.GenTarget, Inc.Heartseed, Inc.InvivoGeniPS Portal, Inc.iXCells BiotechnologiesLonza Group, Ltd.Megakaryon CorporationMerck/Sigma AldrichMetrion Biosciences, Ltd.Miltenyi Biotec B.V. & Co. KGNcardiaNeuCyteNewcells BiotechPancreatic MODY3PeproTechPhenocell SASPlatelet BioGenesisPluricell BiotechPromoCell GmbHQiagenR&D Systems, Inc.ReproCELLRHEINCELL Therapeutics GmbHStemina Biomarker DiscoverySynthego Corp.System Biosciences (SBI)Takara BioTakeda Pharmaceutical Co., Ltd.TEMCELL TechnologiesTempo BioscienceThermo Fisher Scientific, Inc.TreeFrog TherapeuticsVistaGen Therapeutics, Inc.Waisman BiomanufacturingxCell Science, Inc.Yashraj Biotechnology, Ltd. For more information about this report visit https://www.researchandmarkets.com/r/d2jcbt CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

  • MoD contractor Babcock plans to cut 1,000 jobs in UK and overseas

    MoD contractor Babcock plans to cut 1,000 jobs in UK and overseas Company reveals write-offs of £1.7bn and plans to simplify its operations HMS Prince of Wales leaving Rosyth Dockyard in Scotland for the first time. Babcock is the Ministry of Defence’s second-largest contractor. Photograph: Kenny Smith Photography/PA

  • Official Covid deaths lowest for six months as Easter slows registrations – ONS

    The number of registrations in England and Wales was affected by the Good Friday bank holiday, the Office for National Statistics said.

  • Britain to use Brexit "flexibility" to make City of London more attractive

    Britain will use its freedom from European Union rules to regulate markets flexibly and make the City of London even more attractive to global investors, the Financial Conduct Authority said on Tuesday. Britain's financial sector has been largely cut off from the bloc since full Brexit on Dec. 31, with no sign of increased direct access any time soon as the EU builds up capital market autonomy in stock and derivatives trading. Nausicaa Delfas, who heads up the FCA's international division, said Britain's financial market has entered a "new phase", but would remain open to the world and built on "robust" standards.

  • Issue of Equity

    13 April 2021 HARGREAVE HALE AIM VCT PLC (the “Company”) Allotment of Shares The Board announced on 2 September 2020 that the Company had published a prospectus in relation to an offer for subscription of ordinary shares of 1p each (the "Ordinary Shares"), to raise up to £20,000,000 (the "Offer"). The Board announced a Supplementary Prospectus on 8 January 2021. On 12 April 2021 the Company allotted 951,474 Ordinary Shares pursuant to the Offer. The offer price at which 951,474 Ordinary Shares were allotted was 99.18p per Ordinary Share, which was calculated, in accordance with the terms of the Offer, by reference to the net asset value of an Ordinary Share in the Company on 31 March 2021 (as announced on 7 April 2021, being the last published net asset value per Ordinary Share) divided by 0.965 (to allow for the costs of the Offer). Following this allotment, the total number of Ordinary Shares in issue is 231,409,173 with each Ordinary Share carrying one vote each. Therefore, the total voting rights in the Company are 231,409,173. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure Guidance and Transparency Rules. Application will shortly be made for the Ordinary Shares so allotted to be admitted to the Official List of the Financial Conduct Authority and to trading on the London Stock Exchange’s main market for listed securities, and dealings are expected to commence on or around the 16 April 2021. Definitive documents of title are expected to be despatched within 15 business days of allotment. Terms defined in the Prospectus have the same meaning where used in this announcement. END For further information, please contact: JTC (UK) LimitedSusan.FadilRuth WrightHHV.CoSec@jtcgroup.com +44 20 3893 1005 +44 203 893 1011 LEI: 213800LRYA19A69SIT31

  • Small Satellite Market Report 2020-2030

    Forecasts by Mission Type (Constellation Missions, Installation Missions, Replacement Missions), Investor Type (Venture Capital, Public/Private, Crowdfunding, Strategic/Private Equity, Traditional Investment, Government/Foundation), by Type (NanoSatellite, MicroSatellite, MiniSatellite, PicoSatellite, FemtoSatellite), by Application (IoT/M2M, Earth Observation & Meteorology, Military & Intelligence, Scientific Research & Exploration, Weather, Other Applications), by Industry (Satellite Services, Satellite Manufacturing, Launch Vehicles, Ground Equipment).New York, April 13, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Small Satellite Market Report 2020-2030" - https://www.reportlinker.com/p04694759/?utm_source=GNW PLUS, Analysis of Leading Small Satellite CompaniesGlobal small satellites market was valued at US$xx billion in 2019 and is projected to reach at a market value of US$xxbillion by 2030. North America market is expected to grow at a CAGR of xx% during the forecast period 2020-2030. The market is estimated to grow at a CAGR of xx% in the first half period 2020-2025 and is projected to grow at CAGR of xx% in the other half period 2025-2030. Small satellites (smallsats) are an emerging class of spacecraft that incorporates recent software and hardware improvements, most notably ones derived from the IT and electronics industries, and benefits from the resulting high capability feasible in small packages. There is no universally accepted definition of a smallsat; various groups and reports have classified smallsats according to their mass, volume, cost, capabilities, or some combination thereof. In this report, smallsats are defined as satellites with masses lower than 200 kg (with some exceptions). Small satellites include CubeSats, special types of cuboid-shaped smallsats that weigh between 1–10 kg, and are created in units of a 10 cm × 10 cm × 10 cm cube. Compared with traditional satellites, smallsats typically have shorter development cycles, smaller development teams, and, consequently, lower cost, both for the development and for the launch of the satellites. Almost all are planned for launch into LEO orbit; and over 60% will be CubeSats. The analyst used a scenario-based approach to identify key drivers propelling the development and direction of the smallsat sector. After an initial survey of current activities in the sector, the analyst selected four scenarios that could become reality 10–15 years from now. The analyst identified drivers that would lead to these end states, and examined their current status and trends. The analyst also assessed the likelihood of the scenarios coming to fruition between 2020 and 2030. This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today. Key Takeaways • Asia and Europe are strong players in the small satellite field, noted by stakeholders as having important markets and significant technological development • Asia in particular is noted as a growing region in the field, with new start-ups and increasing availability of launch. • Government is the primary source of funding in most emerging countries; although there is limited foreign private (venture capital) funding, such funding has not proliferated into the new space industry as widely as has occurred within the United States. • Countries with a longer space heritage, such as Russia, China, and potentially India, are often perceived as having not fully leveraged their satellite experience for small satellites, with government space programs having placed more emphasis on large satellites. However, this attitude is changing, particularly in China. • South American countries have demonstrated interest in small satellites given a growing number of government sponsored small satellite missions; Academic institutions are key in developing technologies. Market Segments Covered By Type • Mini-Satellite • Micro-Satellite • Nano-Satellite • Pico-Satellite • Femto-Satellite • Other Type By Industry • Satellite Services • Satellite Manufacturing • Launch Vehicles • Ground Equipment By Mission Type • Constellation Missions • Installation Missions • Replacement Missions By Application • IoT/M2M • Communication • Earth Observation & Meteorology • Military & Intelligence • Scientific Research & Exploration • Weather • Other Application Investor Type • Venture Capital • Public/Private • Crowdfunding • Strategic/Private Equity • Traditional Investment • Government/Foundation • Other Investor Types Leading Companies Profiled • Airbus SE • Park Aerospace Corp. • L3Harris Technologies, Inc. • Magellan Aerospace • Lockheed Martin • Maxar Technologies Inc. • Northrop Grumman • ORBCOMM Inc. • The Boeing Company • Thales Group • Dauria Aerospace • ISS Reshetnev • BAE Systems plc • Sierra Nevada Corporation • QinetiQ Group plc • OHB SE What does the future hold for the Small Satellite market? This new study supplies the answer to you and provides it to you NOW. In this new, 714-page report, you will receive 500+ tables and charts as well as independent, impartial, and objective analysis. By ordering and reading this report today, you will be given: • A concise and comprehensive analysis of the Small Satellite market from 2020 to 2030. • An understanding of not only the financial prospects of the Small Satellite industry but also the growth potential of several submarkets – including different application and end-user types. • An informed forecast of the sales of 25 individual countries – Australia, Brazil, Canada, China, France, Germany, India, Israel, Japan, Mexico, Russia, Saudi Arabia, South Korea, Spain, United Arab Emirates, United Kingdom and United States. • A description of the main drivers and restraints that are affecting the development of the Small Satellite market. • Profiles of the key players in the industry as well as up-to-date information on their latest agreements and CSI product developments. Who should read this report? • Senior Executives • Business Development Managers • Marketing Directors • Consultants • Chief Executive Officers • Governments, agencies & organisations actively working or interested in the Small Satellite industry will also find significant value in our research. Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight. This study is for everybody needing commercial analyses for the small satellite market and leading companies. You find data, trends and predictions.Read the full report: https://www.reportlinker.com/p04694759/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

  • The government has made another change to the rules on weddings

    Here are all the rules we know about weddings and wedding receptions taking place after lockdown.

  • Poste: sportelli multietnici per favorire integrazione sociale

    In collaborazione con Postenews Poste Italiane ha aperto 29 uffici multilingua nelle principali città italiane per offrire servizi e andare incontro alle esigenze di tutti gli stranieri che vivono nel nostro Paese. Secondo gli ultimi dati Istat in Italia risiedono 5 milioni e 234 mila stranieri, circa l’8,7% della popolazione totale. “L’intento – spiega Poste - è proporre l’ufficio postale come un luogo di inclusione sociale, dove accoglienza, integrazione, prossimità, dialogo sono atti concreti per una clientela dinamica e altamente operosa”. Gli sportelli multietnici sono stati sperimentati per la prima volta a Roma nell’ufficio di via Marsala, a fianco della stazione Termini, vero e proprio melting pot capitolino, per poi estendersi in città dove le comunità straniere sono più numerose e radicate come nei grandi capoluoghi quali Milano, Napoli, Torino, Firenze, Palermo, Genova, Padova, Bari, Caserta, Foggia. Ma anche a Lecce, Modena, Prato, Mazara del Vallo e Vittoria. Tra i servizi offerti i più richiesti, sottolinea Poste, riguardano la gestione del risparmio, l’invio di corrispondenza, il money transfer, le offerte di telefonia mobile e di polizze assicurative, ma anche la spedizione di pacchi. Gli sportelli multilingua forniscono anche un supporto per affrontare iter burocratici e amministrativi quali la richiesta o il rinnovo del permesso di soggiorno. Agli sportelli si parlano diverse lingue straniere: ovunque inglese, francese e spagnolo, ma anche il romeno. A Prato e Milano si parla soprattutto il cinese, a Roma si aggiungono il bengalese e il filippino, l’arabo a Napoli. In tutti gli uffici personale proveniente da altri continenti lavora al fianco di impiegati italiani poliglotti. Anche la segnaletica multilingue e l’erogatore ticket presenta un modello operativo multilingue associato ai bacini etnici di riferimento di ciascun ufficio postale. Una opportunità utilizzata anche da turisti o studenti Erasmus. Per maggiori approfondimenti https://www.postenews.it/2021/03/26/sostegno-al-territorio-e-ai-clienti-piu-fragili-il-ruolo-sociale-di-poste-italiane-supera-le-barriere/

  • First drive: The MG5 is the UK’s first electric estate car

    The new MG5 promises practicality and value, but can it deliver more than that? Ted Welford finds out.

  • Covid Brasile, Bolsonaro: "Le restrizioni? Sono dittatura"

    Le restrizioni imposte contro il coronavirus come il comunismo e le dittature. Il paragone è del presidente del Brasile, Jair Bolsonaro, "Oggi ti danno modo di capire cos'è il comunismo e qual è il prototipo dei dittatori quelli che decidono il divieto di culto, il coprifuoco, l'espropriazione di beni immobili, le restrizioni alla circolazione", ha scritto il presidente, in un post sul suo profilo Facebook. Nel suo messaggio Bolsonaro, che ha sempre rifiutato le restrizioni nonostante la criticità della situazione sanitaria, ha sottolineato che le misure implicano che "sempre più persone perdono il lavoro" e che "il caos bussa alle porte dei brasiliani ". Poi ha aggiunto: "Chiedetevi cosa può fare ciascuno di noi per il Brasile e la sua libertà". Spiegando che "nei momenti difficili bisogna unire le forze e non offendere chi può essere decisivo nel salvataggio". Il presidente brasiliano ha pubblicato questo messaggio qualche giorno dopo l'ordine, da parte della Corte suprema federale, di aprire una commissione parlamentare per indagare su possibili crimini commessi dal governo nella gestione della crisi sanitaria. Intanto, è polemica per una conversazione privata avuta domenica con il senatore Jorge Kajuru, suo alleato, al quale il presidente chiede di indagare sulla condotta di governatori e sindaci nella gestione della sanità poiché teme che la commissione preparerà "un rapporto sporco". Una nuova parte della conversazione è stata diffusa ieri e, in essa, Karaju dice che non parteciperà alla commissione, contrariamente a quanto chiesto dal presidente, che teme a questo punto che si rafforzi il ruolo del senatore dell'opposizione Randolfe Rodigues. Nell'audio si sente: "Se non partecipi, Randolfe Rodrigues parteciperà e inizierà a rompere le palle, quindi dovrò battere quella m...". Rodrigues, promotore della commissione d'inchiesta, ha commentato: "La violenza è solitamente una via d'uscita per i codardi che hanno molto da nascondere". E, mentre iniziano le indagini, il Brasile ieri ha superato i 13,5 milioni di casi avvicinandosi ai 355.000 morti per Covid.